We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Amgen Files Emergency Motion to Halt Neupogen Biosimilar
Amgen Files Emergency Motion to Halt Neupogen Biosimilar
Amgen made a last-ditch effort to block competition for its chemotherapy product Neupogen, asking the Federal Circuit to stop Sandoz’s Sept. 2 launch of its Zarxio biosimilar.